Liraglutide Pen Injector

Phase 2

MMayo Clinic

Liraglutide Pen Injector is one of 35 therapeutic programs targeting Type 1 Diabetes. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Type 1 DiabetesRecruiting

Type 1 DiabetesPhase 2

Recruiting

Competition

Competitive Landscape

77 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Glucagon

XXeris Pharmaceuticals

Approved

13 2

Repatha

Amgen

Approved

1 3

Zetia

OOrganon and Co

Approved

1 4

Ozempic

Novo Nordisk

Phase 3

7 5

Singulair

Stelara

1 7

Inpefa

LLexicon Pharmaceuticals

Phase 3

5 8

Tricor

JJagotec

Phase 3

2 9

Atorvastatin Calcium

Merck & Co.

Phase 3

1 10

Diamox

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Type 1 Diabetes

NCT06976619

Clinical

Trials by Indication[1]

Type 1 Diabetes1 trial

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People

Recruiting·MMayo Clinic·Phase 2·NCT06976619·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Liraglutide Pen Injector. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Liraglutide Pen Injector. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MMayo Clinic

Liraglutide Pen Injector

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Type 1 Diabetes1 trial

References

Drug Info

Quick Facts

Related News